PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
22.06%
Revenue growth of 22.06% vs. zero growth in Healthcare. Walter Schloss might still want to see if it can translate into profits.
127.38%
Gross profit growth of 127.38% while Healthcare median is zero. Walter Schloss might see a slight advantage that could be built upon.
38.32%
EBIT growth of 38.32% while Healthcare median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
38.32%
Operating income growth of 38.32% while Healthcare median is zero. Walter Schloss might see a modest advantage that can expand.
65.75%
Net income growth of 65.75% while Healthcare median is zero. Walter Schloss might see potential if moderate gains can keep rising.
66.67%
EPS growth of 66.67% while Healthcare median is zero. Walter Schloss might see a slight edge that could compound over time.
66.67%
Diluted EPS growth of 66.67% while Healthcare median is zero. Walter Schloss might see a slight edge that could improve over time.
5.20%
Share change of 5.20% while Healthcare median is zero. Walter Schloss would see if the modest difference matters long-term.
5.20%
Diluted share change of 5.20% while Healthcare median is zero. Walter Schloss might see a slight difference in equity issuance policy.
No Data
No Data available this quarter, please select a different quarter.
293.60%
OCF growth of 293.60% while Healthcare is zero. Walter Schloss might see a modest positive difference, which can compound over time.
184.22%
FCF growth of 184.22% while Healthcare median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
-34.22%
Negative 5Y CAGR while Healthcare median is 0.00%. Seth Klarman would see if others are at least growing moderately, indicating a firm-specific problem.
-9.09%
Negative 3Y CAGR while Healthcare median is 0.00%. Seth Klarman would examine if the sector is otherwise stable, indicating a company-specific issue.
2504.48%
OCF/share CAGR exceeding 1.5x Healthcare median of 11.27% over 10 years. Joel Greenblatt would verify if a unique competitive moat underlies these cash flows.
162.10%
5Y OCF/share growth exceeding 1.5x Healthcare median of 18.61%. Joel Greenblatt might see a strong moat or efficient cost structure driving outperformance.
185.89%
3Y OCF/share growth > 1.5x Healthcare median of 18.06%. Joel Greenblatt might see a recent competitive advantage translating into cash improvements.
-113.65%
Negative 10Y net income/share CAGR vs. Healthcare median of 37.30%. Seth Klarman might see a fundamental problem if peers maintain growth.
-168.21%
Negative 5Y CAGR while Healthcare median is 29.02%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
-153.14%
Negative 3Y CAGR while Healthcare median is 29.67%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
9548.01%
Equity/share CAGR exceeding 1.5x Healthcare median of 28.19% over 10 years. Joel Greenblatt would see if a high ROE underlies this compounding advantage.
-27.53%
Negative 5Y equity/share growth while Healthcare median is 13.34%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
-56.57%
Negative 3Y equity/share growth while Healthcare median is -19.95%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
13.57%
AR growth of 13.57% while Healthcare median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
3.26%
Inventory growth of 3.26% while Healthcare median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
2.91%
We expand assets while Healthcare is negative. Peter Lynch sees a possible advantage if expansions align with profitable markets or a recovering cycle.
-2.10%
Negative BV/share change while Healthcare median is -0.42%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-19.58%
Debt is shrinking while Healthcare median is rising. Seth Klarman might see an advantage if growth remains possible.
271.70%
R&D growth of 271.70% while Healthcare median is zero. Walter Schloss wonders if a slight increase yields a meaningful competitive edge.
36.61%
SG&A growth far above Healthcare median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.